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Injection of high dose botulinum-
toxin A leads to impaired skeletal 
muscle function and damage of the 
fibrilar and non-fibrilar structures
Jessica Pingel1, Mikkel Schou Nielsen  2, Torsten Lauridsen2, Kristian Rix2, Martin Bech  3, 
Tine Alkjaer1, Ida Torp Andersen1, Jens Bo Nielsen1 & R. Feidenhansl2,4
Botulinum-toxin A (BoNT/A) is used for a wide range of conditions. Intramuscular administration of 
BoNT/A inhibits the release of acetylcholine at the neuromuscular junction from presynaptic motor 
neurons causing muscle-paralysis. The aim of the present study was to investigate the effect of high 
dose intramuscular BoNT/A injections (6 UI = 60 pg) on muscle tissue. The gait pattern of the rats 
was significantly affected 3 weeks after BoNT/A injection. The ankle joint rotated externally, the rats 
became flat footed, and the stride length decreased after BoNT/A injection. Additionally, there was 
clear evidence of microstructural changes on the tissue level by as evidenced by 3D imaging of the 
muscles by Synchrotron Radiation X-ray Tomographic Microscopy (SRXTM). Both the fibrillar and the 
non-fibrillar tissues were affected. The volume fraction of fibrillary tissue was reduced significantly 
and the non-fibrillar tissue increased. This was accompanied by a loss of the linear structure of the 
muscle tissue. Furthermore, gene expression analysis showed a significant upregulation of COL1A1, 
MMP-2, TGF-b1, IL-6, MHCIIA and MHCIIx in the BoNT/A injected leg, while MHVIIB was significantly 
downregulated. In conclusion: The present study reveals that high dose intramuscular BoNT/A 
injections cause microstructural damage of the muscle tissue, which contributes to impaired gait.
Botulinum toxin (BoNT/A) is among the most potent toxins to humans that are known1,2. One gram of crystalline 
preparation of BoNT/A can potentially kill 1.000.000 people. In several incidents its use as a biological weapon 
has been attempted3. Nevertheless, BoNT/A is the first biological toxin that has been licensed for treatment of 
human disease after the pioneering work of the ophthalmologist Alan Scott who used BoNT/A for the treatment 
of strabismus4. Today, the list of diseases that are treated by using BoNT/A is long and includes cervical dystonia5, 
blepharospasm6, urinary incontinence7, anal fissure8 and numerous movement disorders9, including cerebral 
palsy10, migrane11, depression12, mandibular recontouring13 and, fascial wrinkles14. Furthermore, BoNT/A con-
tinues to be the most common minimally invasive procedure performed by plastic surgeons and has during the 
past decade grown into a billion dollar industry15.
BoNT/A injection is also commonly used against the development of contractures in patients with central 
motor lesions. However, only a few studies have investigated the effect of BoNT/A injections on the muscle at 
tissue level. Skeletal muscle consists of the contractile proteins myosin and actin, which are incorporated into 
thick and thin filaments, respectively. Together they form arrays in longitudinally repeated banding patterns 
termed sarcomeres. Sarcomeres in series form myofibrils, and many parallel myofibrils exist in each fiber. A 
muscle contraction occurs when an action potential reaches the presynaptic terminal of a motor neuron. This 
activates voltage-dependent calcium channels and allows calcium ions to enter the neuron. Calcium ions bind to 
proteins (synaptotagmin) on synaptic vesicles, triggering vesicle fusion with the cell membrane and subsequent 
neurotransmitter release from the motor neuron into the synaptic cleft. The motor neurons then release acetyl-
choline (ACh), which diffuses across the synaptic cleft and binds to nicotinic acetylcholine receptors (nAChRs) 
on the cell membrane of the muscle fiber, also known as the sarcolemma. The binding of ACh to the receptor 
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depolarizes the muscle fiber, and triggers a series of molecular events that includes the binding of calcium to the 
muscle-regulatory proteins, and causes the interaction between myosin and actin filaments, and subsequently the 
formation of cross-bridges causing muscle contraction.
Botulinum toxin works by blocking the release of acetylcholine from presynaptic motor neurons, and 
this chemical denervation causes a cascade of downstream events in the muscle thus causing muscle paraly-
sis16. BoNT/A asserts its effect by proteolysis of the SNARE protein synaptosyme-associated protein of 25 kDa 
(SNAP25) in the synapses of the motor neurons17. SNAP25 is a cytoplasmic protein, which is crucial in the fusion 
between the membranes of the vesicles containing ACh and the cell membrane at the axon terminal. When 
BoNT/A is injected into muscle tissue, the proteolysis of SNAP25 prevents the exocytosis of ACh, and effectively 
leads to muscle paralysis2,18,19.
Muscle atrophy has been noted as a common side effect as a result of denervation20,21. Furthermore, consid-
erable fiber atrophy has been observed after BoNT/A (5–10 UI) injections into the longissimus dorsi muscle of 
rabbits22. One rat study investigated changes in different muscle proteins after BoNT/A injections (dosage of 5 
units/kg body weight) and observed that the expression of various proteins changed after injection when com-
pared to saline injections23. In fact, thirty-eight proteins were associated with alterations of energy metabolism, 
contractile function of the muscle, transcription and translation, cell proliferation and cellular stress response23. 
In addition, intramuscular BoNT/A injections (Each dose was 6 U/kg, in a 100 µL volume) have been shown to 
induce significant changes of fiber type composition with a shift from faster to slower isoforms24. Nonetheless, it is 
still unclear whether or not the fibrillar structure of the muscle fibers is damaged as a result of BoNT/A injections. 
To resolve this issue a 3D visualizations of the tissue is required. Standard lab-based X-ray tomography does not 
have the sufficient X-ray brilliance to resolve the details of tissue at microstructural level within a reasonable time 
frame. However, Synchrotron Radiation X-ray Tomographic Microscopy (SRXTM) dramatically improves the 
sensitivity within biomedical applications25,26. The tunable-energy monochromatic beam allows us to achieve 
high sensitivity to small variations in mass densities. This makes SRXTM well-suited for imaging biological tissue 
in contrast to conventional X-ray CT25. Within medical science, the modality has been successfully applied to 
study the microstructure of a range of tissues such as the 3D brain anatomy in murine model27, the microvascular 
network and thrombi in hepatocellular carcinoma28 and hyaline cartilage in human knees29. Hence, the SRXTM 
is ideal for the purpose to monitor tissue changes in muscles after high dose BoNT/A injections. In this study, 
x-ray attenuation and phase contrast was taken into consideration by implementation of the Paganin approach30. 
The aim of the present study was to explore the effects of high dose intramuscular BoNT/A injections on healthy 
muscle tissue using SRXTM. This was done to confirm whether or not the muscle tissue maintained its integrity 
and microstructure following BoNT/A injections. In Fig. 1 an example of a 3D reconstruction of the fibrillar 
and the non-fibrallar tissue is shown for a BoNT/A injected muscle and the corresponding control. The scale is 
400 µm × 400 µm × 700 µm. It is clearly seen that the BoNT/A injection causes significant changes in the micro-
structure of the tissue. Most obvious is that the ratio between fibrillary and non-fibrillar tissue changes and that 
the linear structure of the muscle tissue is lost. In order to quantify these changes we calculate the volume fraction 
of the fibrillary tissue and the isotropy index as defined below. As secondary study aims we also investigated the 
effects of high dose BoNT/A injections on both the gait pattern and the gene expression profile in healthy rats.
Results
Volume fraction. The muscle tissue organization was severely affected by the BoNT/A injections 3 weeks 
after injection (Figs 1 and 2) of 20 pg BoNT/A per muscle head (60 pg in total). The amount of the fibrillar tissue 
significantly decreased (p = 0.02), while the non-fibrillar tissue was significantly increased (p = 0.02).
Muscle atrophy. Three weeks after BoNT/A injection the wet weight of the triceps surae was decreased sig-
nificantly (p = 0.00005) by 45% (BoNT/A injected leg (BoNT/A): 0.78 ± 0.03 g and Contralateral saline injected 
leg (Con): 1.43 ± 0.07 g) in the BoNT/A injected leg. A 2D image of the muscle crossections displays the atrophy 
observed in the BoNT/A leg (Fig. 3).
Anisotropy. The isotropy index from the star length distribution (SLD) analysis significantly increased 
(p = 0.002) after the BoNT/A injections (3 weeks post injection), which indicates a loss of linear structure of 
the muscle tissue. This was further supported by visualization of the 3D orientation of the muscle tissue using 
rose diagrams (Fig. 4). The diagram displays the strength of directions of the non-fibrillar tissue in the volume 
of interest (VOI). For linearly structured tissues, the diagram will take the shape of a strongly elongated ellipsoid 
whereas isotropic tissues with uniformly distributed directions will take the shape of a sphere. As seen from Fig. 4, 
the BoNT/A injection has resulted in a loss of directionality of the non-fibrillar tissue.
Gait pattern analysis. The gait pattern of the rats was significantly affected. There was a significant main 
effect of both time (p < 0.0001) and leg (p = 0.0008) on the stride length but not of the interaction. Across time, 
the stride length was significantly reduced for the BoNT/A leg compared to the non BoNT/A leg (p = 0.0006). 
Across legs, the second pre-test stride length value was significantly higher than any post-test values (p < 0.0006 
for all comparisons). No significant differences were observed between the post-tests. There was a significant 
main effect of time, leg and the time-leg interaction on the foot length (p < 0.0001 in all cases) indicating that the 
rats became flat footed after BoNT/A injections. The post hoc test revealed that for the BoNT/A leg the foot length 
was significantly increased in all post-test observations when compared to the pre-test observation (p < 0.0001 in 
all cases). For the non BoNT/A leg, the foot length was significantly shorter at the pre-test compared to the first 
three post-tests (p = 0.004, p = 0.012 and p = 0.028, respectively). However, the last post-test foot length did not 
differ significantly from the pre-test. The foot length of the BoNT/A leg was significantly greater at all post-tests 
compared to the non BoNT/A leg (p < 0.0001 in all cases). The foot angle was measured as indicated in Fig. 5. 
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A positive foot angle indicates external rotation, and a negative foot angle indicates an internal rotation of the 
foot. There was a significant main effect of time, leg and the time-leg interaction on the foot angle (p < 0.0001 in 
all cases). The post hoc test revealed that for the BoNT/A leg all post-test observations were significantly larger 
than the pre-test observation (p < 0.002 in all cases). For the non BoNT/A leg, the foot angle did not signifi-
cantly change from the pre-test to the post-tests. The foot angle of the BoNT/A leg was significantly greater at all 
post-tests compared to the non BoNT/A leg (Fig. 6).
Clinical score assessment. The clinical score dropped significantly already 24 h post injection (p = 0.0001) 
and reached the lowest level on day 3 post injection (p = 0.00001). The rats never recovered during the protocol 
and the clinical score was still decreased three weeks post injection. There was a significant main effect of time on 
the clinical score (p < 0.0001). The post hoc test revealed that all post-test observations were significantly lower 
compared to the pre-test observation (p < 0.0001 in all cases) (Fig. 6).
Gene expression. The gene expression of seventeen gene targets were analyzed in n = 8 rats (Fig. 7). Specific 
gene targets were selected covering the areas of muscle structure, muscle metabolism, Extracellular matrix com-
ponents, connective tissue breakdown and muscle fiber types. There was a significant main effect of both BoNT/A 
treatment (p < 0.001) and gene (p < 0.001) on the gene expressions and a significant interaction (p < 0.001). Post 
Figure 1. 3D visualizations of tomograms from the SRXTM measurements. Shown are the fibrillar (red) and 
non-fibrillar tissue (yellow) of the muscle in BoNT/A injected (A) and control leg (B) of one of the rats (3 weeks 
post injection of 6UI BoNT/A (3 × 20 pg BoNT (2UI)/a ∼ 60 pg BoNT/A in total). The SRXTM data indicate 
that BoNT/A injection causes damage to the muscle tissue structure and organization.
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Figure 2. Volume fraction in percent of the fibrillar (A) and non-fibrillar tissue (B) of the muscle. All data are 
shown as Mean ± SEM. *Indicates a significant difference between BoNT/A and Con leg. Dose of injection 6UI 
BoNT/A (3 × 20 pg BoNT (2UI)/a ∼60 pg BoNT/A in total). The level of significance was p < 0.05.
Figure 3. 2D images of muscle cross sections. Left image control leg, right image BoNT/A injected muscle (3 
weeks post injection). The BoNT/A injected muscle contains smaller muscle fibers than the control muscle, 
indicating muscle atrophy. Arrows are indicating fibrous and non-fibrous tissue. Dose of injection 6UI BoNT/A 
(3 × 20 pg BoNT (2UI)/a ∼60 pg BoNT/A in total). The scale bar equals 50 µm.
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hoc tests revealed a significant upregulation of gene expression in: collagen type 1 (COL1A1), interleukin 6 (IL-6), 
transforming growth factor beta 1 (TGF-β1), matrix metallopeptidase 2 (MMP-2), myosin heavy chain IIA 
(MHCIIA) and myosin heavy chain IIX (MHCIIX). Myosin heavy chain IIb (MHCIIB) was significantly down-
regulated in the BoNT/A leg compared with the control leg.
Figure 4. Star length distribution (SLD) rose diagrams depicting non-fibrillar tissue orientation in BoNT/A (A) 
and control (B) muscle from one of the rats (3 weeks post injection). Dose of injection 6UI BoNT/A (3 × 20 pg 
BoNT (2UI)/a ∼60 pg BoNT/A in total). Distance from origin and colour (violet = minimum, red = maximum) 
indicate relative component value. Red axes show principal component directions and relative magnitudes. 
The boxplot (right C) shows the isotropy index of n = 6 rats shown as Mean ± SEM. *Indicates a significant 
difference between BoNT/A and Con leg, showing an significantly increased anisotropy index after the BoNT/A 
injections, which indicates a loss of linear structure of the muscle tissue. The level of significance was p < 0.05.
Figure 5. Foot step analysis. The hind paws were dipped in ink and the rats ran over graph paper at (A) baseline 
(2 days pre injection), and (B) post (21 days) after BoNT/A injection into the left triceps surae. Dose of injection 
6UI BoNT/A (3 × 20 pg BoNT (2UI)/a ∼60 pg BoNT/A in total). The strife length, foot angle and the foot 
length were analyzed. All parameters were significantly affected in the BoNT/A leg when compared to baseline 
and the control leg (p < 0.05).
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Body weight. The development of the body weight differed significantly between the BoNT/A injected ani-
mals and the Control group (p < 0.0001) (Fig. 8). In addition both groups changed significantly over time (after 
1 week) (p < 0.0001).
Discussion
The main finding of the present study is that the microstructure of the skeletal muscle showed signs of muscle 
damage following high dose BoNT/A injections (3 × 20 pg BoNT (2UI)/a ∼60 pg BoNT/A in total (6UI)), both at 
the fibrillar- and non fibrillar level of the tissue. The 3D tomographs showed that the tissue lost its linear structure, 
and that the structural composition was clearly affected. The anisotropy analysis of the tomograms gives further 
Figure 6. The stride length, foot angle and foot length was analyzed as indicated on Fig. 5. The clinical score 
(A) shows all animals in arbitrary units AU. The foot angle (B) is shown in degrees (°). The stride length (C) 
is shown in mm. And the foot length is shown in mm. In both B,C and D the black triangles represent the 
BoNT/A injected leg, and the open circles represent the contralateral Con injected leg. Dose of injection 6UI 
BoNT/A (3 × 20 pg BoNT (2UI)/a ∼60 pg BoNT/A in total). All data are shown as Mean ± SEM. *Indicates a 
significant difference between BoNT/A and Con leg, #indicates a significant difference from baseline. The level 
of significance was p < 0.05.
Figure 7. The relative changes of gene expression after botulinum toxin injection. The control leg equals 1 and 
all expressions are shown relative to the expression of the control leg. All data are shown as Geo Mean ± SEM. 
*Indicates a significant difference between BoNT/A and Con leg. Dose of injection 6UI BoNT/A (3 × 20 pg 
BoNT (2UI)/a ∼60 pg BoNT/A in total). The level of significance was p < 0.05.
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support to these indications. The isotropy index increased after high dose BoNT/A injection, which indicates that 
the muscle tissue was more randomly oriented following high dose BoNT/A injections.
Botox is used in several different disciplines with many different purposes. In addition, it is becoming more 
and more common for healthy individuals to receive BoNT/A injections, not to cure a disease, but in order to 
improve the appearance. BoNT/A is among others used to sculpt different muscles of the body, including the 
masseter muscles for mandibular recontouring (used for when individuals complaint of a “squared” lower face31 
or the medial and lateral gastrochnemius for calf recontouring (for when individuals complaint of prominent calf 
muscles)31. However, recent studies have expressed some concerns regarding the use of BoNT/A32–34.
The chemical denervation induced by BoNT/A injection prevents muscle contraction and causes a cascade of 
downstream events in the muscle e.g. inflammation, satellite cell activation, oxidative stress, atrophy and metal 
ion imbalance35,36. Whether BoNT/A also has a direct effect on the muscle tissue is unclear. However, it has 
been shown that repeated BoNT/A injections (once a day for 28 days at doses of 1, 3, and 9 ng kg-1 day-1) result 
in pronounced muscle atrophy37 and muscle weakness. In the present study we observed a loss of 45% muscle 
wet weight after three weeks, and we have previously shown that muscle force drops significantly after BoNT/A 
injection using the same dose as in the present study33. In fact several studies report muscle weakness as the most 
common treatment-related adverse event31. Furthermore it has been shown that side effects are temporary and 
often related to usage of high doses38. Even though the use of BoNT/A has been reported to be safe and many 
patients are treated without complications, some studies report unwanted side effects39,40. One study by Blaszczyk 
et al. examined unwanted side effects (adverse events AEs) after BoNT/A injections in 79 cerebral palsy patients41. 
Altogether 95 AE’s were reported in 45 patients. Nineteen patients reported muscle weakness, and four patients 
did report severe adverse events including speech disorders, swallowing difficulties and respiratory troubles. 
These findings indicate that side effects after BoNT/A injection are quite common41. Cerebral palsy patients are 
often treated with BoNT/A in order to improve gait function, and several studies have shown that this treatment 
is safe and without side effects10,42. However, we suggest that the success of the treatment should be evaluated with 
care. We propose that even though patients do not report any unwanted side effects, this does not mean that the 
BoNT/A treatment was successful in these patients per se. In the present study we observed that BoNT/A injec-
tions had a significant effect on the gait pattern of the present rats. The rats developed a flatfoot on the BoNT/A 
injected leg (Fig. 5). Furthermore the clinical score dropped already after 24 hours and did not return to baseline 
within three weeks (Fig. 6). The same observation has been made previously by Ozawa et al.43 after BoNT/A 
injection (dose 5 units/mL). In addition, the BoNT/A injection caused an external rotation of the foot possibly 
to regain balance (Fig. 6). Furthermore, it appears that more and more people question whether the few positive 
effects achieved by BoNT/A injection are actually overcome by the negative effects it has on the muscles32,33,44.
The affected gait after 24 hours is a result of the reduced presynaptic acetylcholine release that follows 
Botulinum toxin injection. BoNT/A cleaves a SNARE protein SNAP25, which is required for exocytosis and as a 
result several downstream events are affected including muscle atrophy. The muscle atrophy induces weakness, 
and the weakness affects the gait pattern. Thus while the gait pattern and clinical score at the early time points 
reflect the neural effects of BoNT/A, atrophy and muscle weakness is likely to contribute to the impairment of gait 
function at the later time points (3 weeks post injection).
Eamus et al. (1999) have shown that a single injection of BoNT/A into the calf increased the length of gastroc-
nemius during gait45. Furthermore, gait analysis of ninety-seven CP patients revealed that muscle strength was 
highly related to muscle function and explained more of the gait variance than spasticity46. Based on the present 
findings we suggest that the desired outcome of BoNT/A treatment in cerebral palsy patients should be recon-
sidered, and future studies should focus on finding a better treatment instead of improving a drug that does not 
entail the desired effects.
Figure 8. The development of the body weight of the rats after botulinum toxin injection. The open squares 
represent control rats (n = 2), and the black dots represent BoNT/A rats (n = 6). All data are shown as 
Mean ± SEM. *Indicates a significant difference between BoNT/A and Con leg. The level of significance was 
p < 0.05.
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Furthermore, whether muscle contouring of the calf muscles influences the gait pattern in humans has not yet 
been investigated, but based on the present findings we suggest that it might be an important point to focus on in 
future investigations as well.
The damage that occurs in the muscle after high dose BoNT/A injection requires a comprehensive remodeling 
process. This is reflected in gene expressions of the present study (Fig. 7). Both the collagen synthesis and collagen 
breakdown is upregulated after BoNT/A injection. This finding is in agreement with previous observations show-
ing increased collagen synthesis at gene expression level three weeks after muscle injury in rats47. On the other 
hand, immobilization causes a decrease of collagen expression48. Thus, the increased collagen synthesis might 
indicate an accelerated tissue remodeling after muscle damage rather than being a result of the denervation due 
to BoNT/A injection (Fig. 7). The anisotropy findings of the present study indicate a loss of tissue orientation, 
which further indicates that the microstructure of the muscle is undergoing an extensive remodeling process. 
Furthermore, the inflammation marker IL-6 was upregulated in the present study. IL-6 is a pleiotropic cytokine 
involved in tissue regeneration and remodeling, indicating an inflammatory response after BoNT/A injection in 
the muscle49. A significantly up-regulation of IL-6 following muscle injury, coinciding with the active period of 
muscle regeneration has been observed previously in mice48. The present upregulation of IL-6 in the BoNT/A 
injected muscle underlines that the high dose BoNT/A injection caused muscle damage. Furthermore, one study 
observed a significant increase of satellite cells after intramuscular botox injections in rabbits50. In resting muscle 
satellite cells remain quiescent, while muscle injury and trauma invokes activation of satellite cells51,52. Numerous 
studies have shown that skeletal muscle satellite cells are essential for muscle fiber repair and regeneration53–55. 
Muscle wasting occurs in a variety of conditions, including muscular dystrophies, cancer cachexia and sarco-
penia56. In the present study the intramuscular BoNT/A injection caused a decrease of muscle mass of (45%). 
In addition, muscle atrophy can affect specific fiber types, involving predominantly slow type 1 or fast type 2 
muscle fibers (slow-to-fast or fast-to-slow fiber type shift)57. Age related muscle wasting (sarcopenia) induces a 
fast-to-slow fibertype shift58,59. Spinal cord injury patients on the other hand experience a type 1 fiber atrophy 
with a slow-to-fast fiber type shift due to disuse60. In the present study a significant upregulation of myosin heavy 
chain IIA and myosin heavy chain IIx expression was demonstrated, while MHCI was unchanged and MHCIIb 
was downregulated (Fig. 7). These results indicate that BoNT/A injections cause a slow-to-fast fibertype shift due 
to upregulation of fast fiber type expression rather than due to atrophy of type 1 fibers. This might be a compensa-
tory process in order to compensate for a significant loss of muscle force and mass after BoNT/A injections which 
has been observed previously after a single injection of 100 μL of BoNT/A of 6.0 units/kg61. However, the present 
findings are in contrast to previous findings showing that BoNT/A injection in the gastrocnemius muscle of rats 
caused a fast-to-slow fibertype shift when rats received either 3,6,12 or 18 UI of BoNT/A18. These contradictory 
findings may be explained by the difference in how long after the BoNT/A injection the tissue was analyzed. The 
present findings reflect the early regeneration phase (3 weeks after injury), while the study by Dodd et al. demon-
strates the long term effect of the damage after BoNT/A injection18. Furthermore, the present study investigated 
mRNA levels only. To clarify whether BoNT/A injections cause a fibertype shift both short- and longterm should 
rather be investigated using proper fibertyping methods, than mRNA expression only. In addition Fig. 3 shows 
qualitative transectional images of the microstructure of the muscle, and makes the effect of BoNT/A visible by 
eye showing that the muscle fibers in the BoNT/A injected leg are smaller and appear with blurred edges, indicat-
ing muscle atrophy of all present muscle fibers. By using Synchrotron Radiation X-ray Tomographic Microscopy 
(SRXTM) the present study revealed that the microstructure of skeletal muscle tissue was significantly damaged 
three weeks after a single injection of BoNT/A in rats. However, whether repeated injections would lead to even 
further damage needs further investigations.
Whether repeated injections of BoNT/A might have unwanted and irreversible effects is still unclear for sev-
eral different treatments. There are to date unfortunately only few studies that have examined the effects on the 
muscle tissue after repeated injections. However, Minamoto et al. investigated the effect of repeated BoNT/A 
injections into the tibialis anterior muscle in rats and observed that a single injection of BoNT/A caused a 50% 
decrease of muscle torque, while a second injection of botox decreased the muscle torque to 95% when compared 
to the pre injection level61. The authors concluded that a second BoNT/A injection caused a profound and per-
sistent loss in muscle function and altered muscle structure61. Unwanted side effects have also been reported in 
cosmetic medicine where cumulative and repeated injections into the masseter muscle for lower face contouring 
can cause different adverse effects including difficulty chewing, speech disturbances and muscle fatigue31.
In addition, the loss of bodyweight after BoNT/A injections might also be characterized as an unwanted side 
effect. In the present study, when the body weight of the rats that were injected with BoNT/A was compared with 
the bodyweight of healthy untreated control rats, it was observed that the body weight was significantly lower in 
the BoNT/A rats one week after the botox injection until the end of the protocol (Fig. 8). This indicates that a 
high dose of BoNT/A affects the bodyweight development of the rats, which might reflect an inhibited growth 
of the rats. Whether this is only experienced after injection of a high dose BoNT/A is unknown, but it is possible 
that a high dose of BoNT/A injection causes systemic effects which are reflected by the body weight of the rats. 
However, there is increasing evidence that BoNT/A inhibits growth both in rats and in humans32,62,63. Gough et 
al. has previously claimed that BoNT/A injections inhibit muscle growth64. In addition, it has been shown that 
the skeletal muscle tissue in rabbits did not fully recover six month post injection (3.5 UI/kg)65. When translating 
this finding into human years this would mean that the skeletal muscle tissue has not fully recovered 16 years after 
injection. However, there is no infallible mathematical formula to calculate the human age of a rabbit because 
its growth and physiological changes during it’s life are very different from the development seen in humans. 
And the existing age equivalence charts are usually based on observations of ages of rabbits from veterinarians. 
Nevertheless, the finding that high dose BoNT/A injections affect both bodyweight development, microstructure 
of the muscle and has an influence on the gait pattern of rats, raises a series of questions towards the rational of 
BoNT/A as a treatment against muscle contractures.
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One major limitation of the present study is that the synchroton data are only analysed at one single time-
point (3 weeks post BoNT/A injection). This limits the ability to draw any major conclusions regarding the use 
of BoNT/A, since we cannot rule out that all the effects we observe here are fully reversible. Thus, long-term 
observations at several time-points are necessary in order to elucidate the recovery of the muscle tissue following 
BoNT/A injections. Furthermore, this study only reflects effects on the muscle tissue after one single injection. 
Future studies should investigate whether additional injections cause additive damage to the microstructure 
and the tissue. Another important issue in the present study is the fact that the injection volume is quite high 
(100 μl) compared to other studies were only 20 μl injection volume has been used66. The high injection volume 
has certainly produced some edema within the muscle tissue. However, the contralateral leg was injected with 
100 μl saline saline as well and showed no signs of muscle damage 3 weeks after injection. However, it should be 
remembered that a high injection volume might increase the risk of systemic effects due to unintended spread of 
BoNT/A. One previous study has shown that high dose injections of botulinum toxin caused sporadic SNAP25 
expression in distal muscles of rats indicating systemic spread but without evidence of transcytosis (dose: 20 µl 
of BoNT/A (3, 10, 30 U/kg)67. Unfortunately we were not able to investigate whether there was any systemic 
spread of BoNT/A in the present rats. However, it is possible that the high dose of BoNT/A injection and the 
high injection volume used in the present study might have caused systemic effects. These might be reflected by 
the reduced increase of body weight in the rats. On the other hand, the reduced increase of body weight in the 
BoNT/A injected rats may also be explained by reduced mobility of the rat due to the impaired muscle function 
caused by the local effect of the injection, but we cannot exclude that it may also be related to a systemic effect of 
the injection, although there were no visible signs of this.
The rats of present study did not lose much bodyweight; they rather showed a reduction of growth, unlike the 
animals used in the pilot study (Supplementary Material Figure 1). This difference in weight loss might be due 
to differences in age and baseline bodyweight. Unlike the rats that were used in the pilot study (Supplementary 
Material Figure 1) the rats from the present protocol were still growing, and this process might have counteracted 
the weight loss that was induced by the high dose BoNT/A injections.
Conclusion
The present study leads to serious concerns regarding BoNT/A treatment because of the significant effect it has 
on the micro structure of the muscle tissue and tissue organization. Furthermore the results of the present study 
highlight that it is possible that intramuscular high dose BoNT/A injections might cause unwanted side effects 
such as muscle atrophy, and fatigue which causes an extensive remodeling process in the muscle tissue. The 
present findings indicate that high dose BoNT/A injections causes damage of the microstructure of the muscle 
tissue. Furthermore the present study shows that the physical capabilities are significantly reduced and the gait is 
significantly compromised 3 weeks after a high dose BoNT/A injection into the calf.
Materials and Methods
Animals. All experiments were conducted in accordance with the guidelines of EU Directive 2010/63/EU and 
were approved by the Danish Animal Experiments Inspectorate. 23 samples in the form of male Sprague Dawley 
rats (weight: 360 g) were used for the present experiment (n = 4 pilot gait analysis and clinical score (Baseline + 21 
days post injection); n = 8 gait analysis and clinical score (21 days), n = 8 gene expression analysis and volume 
fraction (21 days post injection), n = 1 sham injection (Saline) gene expression normalization, and n = 2 control 
rats for body weight assessment. The rats were caged two by two (2 rats in each cage) in a 12/12 light dark cycle 
with access to water and food ad libitum. All recommended procedures for safe and proper handling, storage 
and preparation for experimental use, and disposal of Botulinum Toxin were complied. (https://www.cdc.gov/
biosafety/publications/bmbl5/bmbl5_sect_viii_g.pdf). The entire medial gastrocnemius (including the injection 
site) of the muscle was dissected and harvested 21 days after BoNT/A injection and was used for gene expression 
analyses and volume fraction measurements. The tissue was harvested while the animals were anesthetized by 2% 
isoflurane. After the harvest the animals were euthanized using pentobarbital injections into the heart while the 
animals still were under anesthesia (2% isoflurane).
Gait pattern analysis. The paws of both hind limbs of the rats were dipped in ink on a stamp pad. Then 
they were put down on a piece of graph paper and run through a plastic tunnel into a dark box. This procedure 
was then repeated three times. All paper strips were digitalized and analyzed using ImageJ (http://imagej.net/
Welcome University of Wisconsin-Madison). The measurements of stride length, foot angle and foot length was 
done as indicated in Fig. 5.
Tissue preparation. The rats were anesthetized by 2% isoflurane. The medial gastrocnemius was removed 
and dissected into smaller pieces with a scalpel (Swann-Morton, Mediq danmark A/S). The wet weight of the 
triceps surae was measured immediately after removal. One piece of the medial gastrocnemius was snap frozen 
in liquid nitrogen and stored at −80 °C for further PCR analysis. Another piece was fixed in Bouin’s fluid for 24 h 
and kept at 4 °C in 1.5 ml Eppendorf tubes. The tissue were then transferred into fresh tubes with 96% ETOH and 
remained at 4 °C until subsequently analysis.
The Clinical score assessment and gait analysis were conducted in four rats in a pilot study where baseline 
measurements and 21 days post measurements were obtained (Fig. 6). Subsequently eight rats were followed 
closely for 21 days and the clinical score and gait analysis was assessed every second day to monitor the acute 
effects over time after BoNT/A injection (Fig. 6).
Injections. In order to test the dosage and injection volume a pilot study was conducted to test the optimal 
dosage (The optimal dose was defined as the smallest dose that would cause the desired effect of muscle atrophy, 
without causing any distress for the animals) (Results shown in Supplementary Material Figure 1). All animals 
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were anesthetized with 2% isoflurane. Both hind limbs were shaved, and the skin was disinfected. Then a high 
dose of BoNT/A was injected (1 BoNT/A Unit = 10 picogram). The present high dose injection was 6 UI in 
total (6 UI = 60 pg in total) and (2 UI = 20 pg per 100 µl saline was injected per muscle head (Botulinum-toxin A 
(BoNT/A® Allergan INC. Irvine CA)) of was injected into the triceps surae (medial gastrocnemius, the lateral 
gastrocnemius and soleus) muscle using a 0.5 ml syringe (Omnican® 20 BRAUN, Germany), and 100 µl saline 
was injected per muscle head in the contralateral control leg. Each rat thereby received a total of 300 µl and 6UI 
of BoNT/A. Until termination of the experiment the welfare of the rats were routinely checked (e.g. for signs of 
dehydrations or distress). The rats were weighed every day following the injection in order to monitor weight 
loss. When any weight loss occurred the rats got 5 ml subcutaneous saline injections twice a day until the body 
weight was regained. The rats used in Clinical locomotion score assessment: The clinical evaluation system by 
(Malmsten 1983) was used to estimate the time course of improvement of motor performance in the hind limbs 
following BoNT/A injections68. The animals were tested at the following timepoints: 2 days pre injection and 2 
days, 4 days, 7 days, 14 days and 21 days post injection. This is a system which scores the movement ability on a 
scale from 1 to 8 (1: no active movements of the limb, 2: few involuntary movements when handling the animal, 3: 
few uncontrolled gait movements with long breaks, 4: leg is used for locomotion without control, 5: leg is used for 
locomotion with little control, 6: leg is used for locomotion with increasing control, 7: Abnormal movements are 
only seen during close observation, 8: normal gait). The animals are observed while they walk voluntarily around 
in their cages for aprox 3 minutes, and the same observer rates the clinical score from 1 to 8.
RNA extraction and real time-PCR analysis. Total RNA isolation: Total RNA was extracted from frozen 
muscle samples from n = 8 BoNT/A rats by using 1 ml of TRI Reagent (Molecular Research Centre, Cincinnati, 
OH) 5 steel beads (2.3 mm) and 1 silica bead (1.0 mm Silicon Carbide Beads (454 grams) BioSpec Products Inc.). 
Extracted RNA was precipitated from the aqueous phase with isopropanol and was washed with ethanol (75%), 
dried and suspended in 10 μl of nuclease-free water. The RNA concentration was determined using a RiboGreen 
RNA Quantitation kit 200–2000 Assays, Molecular Probes USA. RNA quality was determined on the basis of a 
RNA 6000 nano Chip assay kit, Agilent Technologies, Germany. The RNA samples were stored frozen at −20 °C 
until subsequent use in real-time RT-PCR procedures. To test the quality of the extracted RNA an electrophoresis 
in an agarose gel was made. The RNA quality was suggested to be satisfactory for further analysis.
cDNA synthesis. 150 ng RNA was reverse transcribed for each muscle sample in a total volume of 20 μl by 
using the Qiagen Omniscript RT Kit at 37 °C for 1 hour followed by 70 °C for 15 minutes. The resulting cDNA 
was diluted twenty times in dilution buffer (10 mM Tris EDTA buffer: Sigma Germany) + Salmon Testes DNA 
(1ng/μl; Sigma Germany), and samples were stored at −20 °C until used in the PCR reactions for specific mRNA 
analysis.
Polymerase Chain Reaction. The Real-time PCR-method using Glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) and 60S acidic ribosomal protein P0 (RPLP0) as reference genes to study specific mRNA’s of 
interest was applied. However, since both reference genes were significantly affected of the BoNT/A injections, 
all data were normalized to the median values of the control samples of all animals. The primers were purchased 
from MWG Biotech. For each target cDNA the PCR reactions were carried out under identical conditions by 
using 5 μl diluted cDNA in a total volume of 25 μl QuantiTect SYBR Green PCR Mix (Qiagen) and 100 nM of 
each primer (Table 1). The amplification was monitored in real-time using a MX3005 P real-time PCR machine 
(Stratagene, CA). The threshold cycle (Ct) values were related to a standard curve made with cloned PCR products 
Gene Sense Anti sense P-values
RPLP0 AGGGTCCTGGCTTTGTCTGTGG AGCTGCAGGAGCAGCAGTGG <0.001*
GAPDH CCATTCTTCCACCTTTGATGCT TGTTGCTGTAGCCATATTCATTGT <0.001*
Col1A1 ATCAGCCCAAACCCCAAGGAGA CGCAGGAAGGTCAGCTGGATAG 0.006*
Col3A1 TGATGGGATCCAATGAGGGAGA GAGTCTCATGGCCTTGCGTGTTT 0.059
DCN CACTCCAGGAGCTTCGACTCCAC AGTGGGTTGCCGCCCAGTTC 0.131
FMOD CCGTCAACACCAACCTGGAGAA CGTGCAGAAACTGCTGATGGAGA 0.262
FN1 GGGCTTTGGCAGTGGTCATTT CTCATCCGCTGGCCATTTTCTC 0.055
GLUT4 CTTCATCGTTGGCATGGGTTTC CAAATGTCCGGCCTCTGGTTTC 0.594
Itga7 GCTGAGAAGAGAAACGTGAC GTAGAGTGGGCAGCTGAATA 0.135
Prelp CACCTGTACCTCAACAACAATA GAAGTCATGGAAGGCCACTA 0.142
IL6 GACAAAGCCAGAGTCATTCAGAGCA GAGCATTGGAAGTTGGGGTAGGA <0.001*
MMP2 CTGGGTTTACCCCCTGATGTCC AACCGGGGTCCATTTTCTTCTTT 0.017*
TGFb1 CCCCTGGAAAGGGCTCAACAC TCCAACCCAGGTCCTTCCTAAAGTC 0.046*
MHCIb ATTGCCGAGTCCCAGGTCAACA GCTCCAGGTCTCAGGGCTTCAC 0.161
MHCIIA GAAGAGCCGCGAGGTTCACAC GGGACATGACCAAAGGCTTCACA <0.001*
MHCIIB GCCGAGTCCCAGGTCAACAAG TGTGATTTCTTCTGTCACCTTTCAAC <0.001*
MHCIIX GCCGAGTCCCAGGTCAACAA CTCATCTCTTTGGTCACTTTCCTGCT 0.042*
Table 1. PCR primers.
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to determine the relative difference between the unknown samples, accounting for the PCR efficiency. The speci-
ficity of the PCR reaction was confirmed by melting curve analysis after amplification. The real-time PCR condi-
tions were as follows: to denaturate the DNA strands the reaction mix was heated above the melting temperature 
of DNA (95 °C) for 10 minutes, followed by 50 cycles each of 15 seconds at 95 °C, followed by the annealing step 
where optimal primer hybridization conditions were obtained by lowering the temperature to 58 °C for 30 sec-
onds, and the extension step, where the reaction mix was heated to 63 °C for 90 seconds.
Synchrotron radiation x-ray tomographic microscopy (SRXTM). The SRXTM measurements were 
carried out at the TOMCAT (TOmographic Microscopy and Coherent rAdiology experimenTs) beamline at the 
Swiss Light Source69. The X-ray source is a superbending magnet radiation source located 25 m from the sample. 
A double crystal multilayer monochromator was placed 7 m downstream of the source to extract monochromatic 
X-ray photons at 25 keV. The detector system consisted of a 100 μm thick, Ce-doped LuAG (Lutetium Aluminum 
Garnet) scintillator which converted the transmitted X-rays into visible light, a high numerical-aperture micro-
scope which gave a 20 fold magnification, and a pco.edge5.5 16-bit CMOS (Complementary metal–oxide–sem-
iconductor) based camera to record the images. The resulting field-of-view (FoV) was 0.832 mm × 0.702 mm 
(width × height), and the effective pixel size was 325 nm. Muscle biopsies were placed in a 96% ETOH buffer in 
a small 0.2 ml Eppendorf tube and soldered to a holder with beeswax. The sample was placed 63 mm in front of 
the scintillator. Since the sample was larger than the FoV, local tomographic measurements were conducted by 
collecting 1501 projections of 600 ms exposure time over a 180 degree rotation. Flat-beam images (i.e., images 
taken with no sample) and dark images (i.e., images taken with no beam) were obtained in order to correct the 
projections. The total measuring time for all 21 samples took about 24 hours including sample mounting.
The 63 mm distance between sample and detector, combined with an effective pixel size of 325 nm, lead to 
refraction-induced intensity effects in the images. In order to account for this, refraction corrections were per-
formed in using a local implementation at TOMCAT of a single image first order refraction correction algorithm. 
The algorithm used the Paganin approach with the assumption that the object consisted of a homogeneous soft 
tissue material and that the propagation distance was sufficiently short for the transport-of-intensity-equation to 
apply30. For tomographic reconstruction, a filtered back-projection based algorithm was applied.
Image analysis. The background of the slices in the reconstructed tomogram suffered from a low-frequency 
bias-field. A correction was applied by first subtracting a constant plane and then subtracting a linear radial pro-
file. The two correction functions were found by applying a least-squares fit to the mean of the tomogram stack 
slices.
For segmentation into a non-fibrillar and fibrillar phase, an alpha-level Markov random field (MRF) segmen-
tation was applied to the tomograms as described by Pedersen et al.70. First, the data was modeled as a mixture of 
distribution functions by assigning a probability distribution to each phase. After assigning probability distribu-
tions, the spatial information of the data was incorporated into the segmentation process by modeling the data 
as an isotropic MRF71. The MRF smoothing parameter was set to 0.5. To find the optimal segmentation solution 
the multi-labeling problem was solved using graph cuts with alpha expansions as described in Boykov et al.72.
BoNT/A is expected to alter the microstructural tissue of the muscle and changes the fibrillary organization. 
This is evident from Fig. 1, where typical images are shown. Clearly, the ratio between the non-fibrillar and 
fibrillary structure is change significantly which indicates muscle atrophy and tissue damage. Furthermore, the 
anisotropy in the tissue structure is altered (3 weeks post BoNT/A injection, when compared to the contralateral 
control leg). In order to quantify these changes we have evaluated the tomograms.
Volume fraction (percent object volume). The tomograms visualize the muscle tissue around the injection site. 
From the segmented tomograms (3 weeks post BoNT/A injection, when compared to the contralateral control 
leg), volume fractions for the identified non-fibrillar and fibrillar phases were calculated as the percent object vol-
ume (POV) values. Image analysis as well as visualization of the tomograms was performed using custom made 
software implemented in MATLAB (Mathworks, Inc., Natick, MA).
Anisotropy. The anisotropy analysis was performed 3 weeks post BoNT/A injection, and compared to the 
contralateral control leg, with a star length distribution (SLD) analysis using the Quant3D software as described 
elsewhere73,74. A volume of interest (VOI) from the non-fibrillar segmentation was used as an input to the SLD in 
Quant3D. For the orientation parameters, a uniform setting with 513 orientations, random rotations, and dense 
vectors were applied using 10,000 random points for calculating the SLD. The SLD analysis produces a number 
of anisotropic descriptors as described in68. As a measure of the orientation of the non-fibrillar tissue, the isot-
ropy index was used. A value of one reflects a completely isotropic structure whilst zero reflects an anisotropic 
one. An assumption for the anisotropy analysis is that all the connected non-fibrillar tissue has been identified 
in the segmentation of the tomograms. Since the segmentation can have difficulties for samples with a very low 
non-fibrillar volume fraction, a lower threshold of 5% has been set. Two samples with a volume fraction below 
this threshold were excluded.
Data availability. Due to the enormous amount of data, the datasets generated during and/or analysed dur-
ing the current study are available from the corresponding author on reasonable request.
Statistics. All data are presented as Mean ± SEM. Level of significance was set at 5% (p < 0.05).
Clinical score. Changes in the clinical score from the second pre-test to the seventh post-test were investi-
gated using an ANCOVA for repeated measures with time as an independent factor and the first pre-test value as 
a covariate. In case of significant main effect, a post hoc test was applied with Tukey correction for multiple com-
parisons. Gait analysis: Changes from the second pre-test to the fourth post-test in gait function measures (stride 
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length, foot angle and foot length) were investigated using an ANCOVA for repeated measures with time and leg 
(BoNT/A leg and non BoNT/A leg) as independent factors and an interaction of time and leg. The first pre-test 
value was set as a covariate. In case of a significant main effect, a post hoc test was applied with Tukey correction 
for multiple comparisons. Volume fraction and anisotropy: Volume fraction and anisotropy was analyzed using 
a paired Students T-Test. Gene expression: Changes in gene expression between the BoNT/A leg and the control 
leg were investigated using a 2-Way ANOVA analysis with gene targets and leg (BoNT/A leg and control leg) as 
independent factors and an interaction of gene targets and leg. In case of a significant main effect, a post hoc test 
was applied with Tukey correction for multiple comparisons. All p-values from the post hoc tests are shown in 
Table 1. Changes in the development of body weight were investigated using a 2-Way ANOVA analysis with treat-
ment and time as independent factors and an interaction of treatment and time. All PCR data are presented as 
the geo mean ± backtransformed SEM. Statistics software: Statistical calculations for gait analysis and the clinical 
score were performed in SAS Enterprise Guide (SAS Institute Inc. NC, USA 2015, version 7.11). The statistical 
calculations for changes in gene expressions and volume fraction were performed in Sigma Plot (Systat Software 
Inc. USA, version 12.5). Figures 1, 4 and 6 were generated in graphpad Prism 6.04 (GraphPad Software, Inc. CA, 
USA).
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